Form 8-K - Current report:
SEC Accession No. 0001104659-26-044952
Filing Date
2026-04-17
Accepted
2026-04-17 17:00:30
Documents
13
Period of Report
2026-04-15
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2612008d1_8k.htm   iXBRL 8-K 29340
2 EXHIBIT 4.1 tm2612008d1_ex4-1.htm EX-4.1 65146
3 EXHIBIT 4.2 tm2612008d1_ex4-2.htm EX-4.2 319271
  Complete submission text file 0001104659-26-044952.txt   638775

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA btai-20260415.xsd EX-101.SCH 3047
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20260415_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20260415_pre.xml EX-101.PRE 22380
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2612008d1_8k_htm.xml XML 3090
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 26872477
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)